Eisai bags $160 million from sale of Fycompa US rights

20 December 2022

Japanese drugmaker Eisai (TYO: 4523) saw its shares fall nearly 4% to 9,038 yen today, after it announced it is divesting US rights to its anti-epileptic drug Fycompa (perampanel) to Catalyst Pharmaceuticals (Nasdaq: CPRX), whose shares moved up 7.4% to $17.63 on the news.

Eisai has also granted Catalyst an exclusive option period to evaluate and negotiate the acquisition of a rare epilepsy compound in Eisai's pipeline.

Eisai will maintain its rights to Fycompa in countries and regions outside the USA and continue to contribute to patients with epilepsy. Closing of the transaction is contingent on completion of review under antitrust laws in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK